Real-world experience of atezolizumab and bevacizumab for treatment of advanced hepatocellular carcinoma in a single tertiary center

被引：0
|
作者：
Raharjo, C. V. [1 ]
Joseph, R. [1 ]
Stratton, E. [1 ]
Levy, M. [1 ,2 ]
Prakoso, E. [1 ,3 ]
机构：
[1] Liverpool Hosp, Dept Gastroenterol, Liverpool, England
[2] Univ New South Wales, Sydney, Australia
[3] Univ Sydney, Sydney, NSW, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
106
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [21] Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
    Yumita, Sae
    Ogasawara, Sadahisa
    Nakagawa, Miyuki
    Maruta, Susumu
    Okubo, Tomomi
    Itokawa, Norio
    Iino, Yotaro
    Obu, Masamichi
    Haga, Yuki
    Seki, Atsuyoshi
    Kogure, Tadayoshi
    Ishino, Takamasa
    Ogawa, Keita
    Fujiwara, Kisako
    Iwanaga, Terunao
    Fujita, Naoto
    Sakuma, Takafumi
    Kojima, Ryuta
    Kanzaki, Hiroaki
    Koroki, Keisuke
    Inoue, Masanori
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Kanogawa, Naoya
    Saito, Tomoko
    Kondo, Takayuki
    Nakagawa, Ryo
    Nakamoto, Shingo
    Muroyama, Ryosuke
    Chiba, Tetsuhiro
    Itobayashi, Ei
    Atsukawa, Masanori
    Koma, Yoshihiro
    Azemoto, Ryosaku
    Ito, Kenji
    Mizumoto, Hideaki
    Kato, Jun
    Kato, Naoya
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [22] Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian center
    Ng, Kennedy
    Wong, Lawrence Wen Jun
    Choo, Su Pin
    Tai, David Wai-Meng
    Tan, Sze Huey
    Ang, Andrea Jing Shi
    Lee, Joycelyn Jie Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [23] Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center
    Ng, Kennedy Yao Yi
    Wong, Lawrence Wen Jun
    Ang, Andrea Jing Shi
    Tan, Sze Huey
    Choo, Su Pin
    Tai, David Wai-Meng
    Lee, Joycelyn Jie Xin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (05) : E249 - E261
  • [24] Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States
    Singal, Amit G.
    Ozgurdal, Kirhan
    Fan, Xiaozhou
    Vassilev, Zdravko
    Pan, Xiaoyun
    Multani, Jasjit K.
    Chen, Chi-Chang
    Zhou, Zifan
    He, Jing
    Pisa, Federica
    CANCERS, 2023, 15 (23)
  • [25] CHILD-PUGH CLASS DETERMINES THE OUTCOME OF PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB-A REAL-WORLD EXPERIENCE
    Kulkarni, Anand V.
    Krishna, Vamshi
    Patodiya, Bharat
    Shaik, Sameer
    Khan, Arif
    Sharma, Mithun
    Da, Pramod K.
    Reddy, Nageshwar D.
    Rao, Padaki Nagaraja
    HEPATOLOGY, 2022, 76 : S1435 - S1435
  • [26] Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
    Chon, Young Eun
    Kim, Dong Yun
    Kim, Mi Na
    Kim, Beom Kyung
    Kim, Seung Up
    Park, Yong
    Ahn, Sang Hoon
    Ha, Yeonjung
    Lee, Joo Ho
    Lee, Kwan Sik
    Kang, Beodeul
    Kim, Jung Sun
    Chon, Hong Jae
    Kim, Do Young
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (03)
  • [27] Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
    Yuka Hayakawa
    Kaoru Tsuchiya
    Masayuki Kurosaki
    Yutaka Yasui
    Shun Kaneko
    Yuki Tanaka
    Shun Ishido
    Kento Inada
    Sakura Kirino
    Koji Yamashita
    Tsubasa Nobusawa
    Hiroaki Matsumoto
    Tatsuya Kakegawa
    Mayu Higuchi
    Kenta Takaura
    Shohei Tanaka
    Chiaki Maeyashiki
    Nobuharu Tamaki
    Hiroyuki Nakanishi
    Jun Itakura
    Yuka Takahashi
    Yasuhiro Asahina
    Ryuichi Okamoto
    Namiki Izumi
    Investigational New Drugs, 2022, 40 : 392 - 402
  • [28] Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
    Hayakawa, Yuka
    Tsuchiya, Kaoru
    Kurosaki, Masayuki
    Yasui, Yutaka
    Kaneko, Shun
    Tanaka, Yuki
    Ishido, Shun
    Inada, Kento
    Kirino, Sakura
    Yamashita, Koji
    Nobusawa, Tsubasa
    Matsumoto, Hiroaki
    Kakegawa, Tatsuya
    Higuchi, Mayu
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Tamaki, Nobuharu
    Nakanishi, Hiroyuki
    Itakura, Jun
    Takahashi, Yuka
    Asahina, Yasuhiro
    Okamoto, Ryuichi
    Izumi, Namiki
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 392 - 402
  • [29] Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort
    de Castro, Tiago
    Welland, Sabrina
    Jochheim, Leonie
    Leyh, Cathrine
    Shmanko, Kateryna
    Finkelmeier, Fabian
    Jeliazkova, Petia
    Jefremow, Andre
    Gonzalez-Carmona, Maria A.
    Kandulski, Arne
    Roessler, Daniel
    Ben Khaled, Najib
    Enssle, Stefan
    Venerito, Marino
    Fruendt, Thorben W.
    Schultheiss, Michael
    Djanani, Angela
    Pangerl, Maria
    Maieron, Andreas
    Wirth, Thomas C.
    Marquardt, Jens U.
    Greil, Richard
    Fricke, Christina
    Guenther, Rainer
    Schmiderer, Andreas
    Bettinger, Dominik
    Wege, Henning
    Scheiner, Bernhard
    Mueller, Martina
    Strassburg, Christian P.
    Siebler, Juergen
    Ehmer, Ursula
    Waidmann, Oliver
    Weinmann, Arndt
    Pinter, Matthias
    Lange, Christian M.
    Saborowski, Anna
    Vogel, Arndt
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (11)
  • [30] Real-world outcomes of patients with advanced-stage hepatocellular carcinoma receiving combination therapy with atezolizumab and bevacizumab: A South Australian statewide experience
    Chan, A.
    Saluja, H.
    Nind, G.
    Singhal, N.
    Roy, A.
    Mcgregor, M.
    Chinnaratha, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 56 - 57
12345